ICMJE DISCLOSURE FORM

Date: April 8, 2022
Your Name: Eziafa Oduah
Manuscript Title: The Emerging Landscape of EFGR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma – Successes and Challenges
Manuscript number (if known): JTD-22-432

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | Time frame: Since the initial planning of the work |
|   | No time limit for this item.                                                                   |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                      | None                                                                              |
| 3 | Royalties or licenses                                                                         | None                                                                              |
| 4 | Consulting fees                                                                               | None                                                                              |
| 5 | None                                                                                         |                                                                                  |
|   |                                                                 |   |
|---|----------------------------------------------------------------|---|
| 1 | Payment or honoraria for lectures, presentations,              |   |
|   | speakers bureaus, manuscript writing or educational events     |   |
| 6 | Payment for expert testimony                                   | None |
| 7 | Support for attending meetings and/or travel                   | None |
| 8 | Patents planned, issued or pending                             | None |
| 9 | Participation on a Data Safety Monitoring Board or             | None |
|   | Advisory Board                                                |   |
| 10| Leadership or fiduciary role in other board, society,          | None |
|   | committee or advocacy group, paid or unpaid                    |   |
| 11| Stock or stock options                                        | None |
| 12| Receipt of equipment, materials, drugs, medical writing, gifts | None |
|   | or other services                                              |   |
| 13| Other financial or non-financial interests                     | None |

Please summarize the above conflict of interest in the following box:

I have no conflicts of interests as it pertains to this manuscript.

Please place an “X” next to the following statement to indicate your agreement:

_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: __April 8, 2022__
Your Name: __Chung-Shien Lee__

**Manuscript Title:** The Emerging Landscape of EFGR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma – Successes and Challenges

**Manuscript number (if known):** __JTD-22-432__

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | **Time frame: Since the initial planning of the work**  
___None
 |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                     | **Time frame: past 36 months**  
___None |
| 3 | Royalties or licenses                                                                         | ___None |
| 4 | Consulting fees                                                                             | ___Consultant  
Pharmacy Times, Annenberg, Health First, Amida Care |

Specifications/Comments (e.g., if payments were made to you or to your institution)
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | Honoraria for lectures | Identification of ALK and ROS1 Biomarkers and Appropriate Treatment in the Management of Non–Small Cell Lung Cancer (Pharmacy Times) |
|---|---|---|---|
|   |   |   | Targeting Lung Cancer with a Focus (American College of Clinical Pharmacy) |
|   |   |   | Evaluating The Starting Dose of Tyrosine Kinase Inhibitors In Solid Tumors, Do We Have It Right? (HOPA Annual Conference) |
|   |   |   | HOPA Mentorship Program Update |
| 6 | Payment for expert testimony | None |   |
| 7 | Support for attending meetings and/or travel | None |   |
| 8 | Patents planned, issued or pending | None |   |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | Advisory board participation | G1 Therapeutics, Takeda |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | Leadership positions | Member, HOPA Publication committee |
|   |   |   | President, Long Island Society of Health-System Pharmacists |
|   |   |   | Chair, NYSCHP Education and Professional Development Committee |
|   |   |   | Chari, NYSCHP Oncology Symposium |
| 11 | Stock or stock options | None |   |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |   |
| 13 | Other financial or non-financial interests | None |   |

Please summarize the above conflict of interest in the following box:

Dr. Lee reports consulting fees from Pharmacy Times, Annenberg, Health First and Amida Care. Dr. Lee reports honoraria for lectures from Pharmacy Times, American College of Clinical Pharmacy, HOPA Annual Conference and HOPA Mentorship Program Update. Dr. Lee serves on the advisory board of G1 Therapeutics and Takeda. Dr. Lee serves as member of HOPA Publication Committee, President of Long Island Society of Health-System Pharmacists, Chair of NYSCHP Education and Professional Development Committee, and Chair of NYSCHP Oncology Symposium. Dr. Lee has no conflicts of interests as it pertains to this manuscript.

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.
ICMJE DISCLOSURE FORM

Date: April 8, 2022
Your Name: Nagarashee Seetharamu
Manuscript Title: The Emerging Landscape of EFGR Tyrosine Kinase Inhibitors in Lung Adenocarcinoma – Successes and Challenges
Manuscript number (if known): JTD-22-432

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| **Time frame: Since the initial planning of the work** |                                                                                   |                                                                                  |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | None                                                                            |
|   | **No time limit for this item.**                                                                 |                                                                                  |
| **Time frame: past 36 months** |                                                                                   |                                                                                  |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above).                      | None                                                                            |
| 3 | Royalties or licenses                                                                         | None                                                                            |
| 4 | Consulting fees                                                                               | -None                                                                           |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, Honoraria for lectures    | OncLive Thoracic oncology updates- institutional perspectives 2020              |
|   |   |   |
|---|---|---|
|   | manuscript writing or educational events |   |
| 6 | Payment for expert testimony | None |
| 7 | Support for attending meetings and/or travel | None |
| 8 | Patents planned, issued or pending | None |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | Advisory board participation Amgen, AstraZeneca, Blueprint pharma, Takeda, Regeneron, Merck, Genentech, Boehringer Ingram |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | Leadership positions Member, Alliance Oncology Preventions Committee Member, Alliance Oncology Respiratory Committee IASLC, publications committee ASCO, virtual mentorship committee |
| 11 | Stock or stock options | None |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | None |
| 13 | Other financial or non-financial interests | None |

Please summarize the above conflict of interest in the following box:

Dr. Seetharamu reports honoraria for lectures sponsored by OncLive and Total Health Conferencing. Dr. Seetharamu serves on the advisory board of AstraZeneca, Blueprint pharma, Takeda, Regeneron, Merck, Genentech, Boehringer Ingram and Mirati. Dr. Seetharamu serves as a member of Alliance Oncology Preventions Committee, member of Alliance Oncology Respiratory Committee, publications committee of IASLC and virtual mentorship committee of ASCO. Dr. Seetharamu has no conflicts of interests as it pertains to this manuscript.

Please place an “X” next to the following statement to indicate your agreement:

_X_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.